People: GTX Inc (GTXI.W)
GTXI.W on CBOE When Trading NASDAQ Global Select Market
6.49USD
23 May 2013
6.49USD
23 May 2013
Price Change (% chg)
$0.18 (+2.85%)
$0.18 (+2.85%)
Prev Close
$6.31
$6.31
Open
$6.06
$6.06
Day's High
$6.53
$6.53
Day's Low
$6.06
$6.06
Volume
2,100
2,100
Avg. Vol
574
574
52-wk High
$7.00
$7.00
52-wk Low
$2.62
$2.62
Summary
| Name | Age | Since | Current Position |
|---|---|---|---|
Joseph Hyde |
70 | 2000 | Independent Chairman of the Board |
Marc Hanover |
50 | 2011 | President, Chief Operating Officer |
Mitchell Steiner |
52 | 1997 | Chief Executive Officer, Vice Chairman of the Board |
Mark Mosteller |
50 | 2005 | Chief Financial Officer, Vice President |
James Dalton |
50 | 2011 | Vice President, Chief Scientific Officer |
Henry Doggrell |
64 | 2012 | Vice President, Chief Legal Officer, Secretary |
Michael Carter |
75 | 2006 | Independent Director |
Barrington Furr |
69 | 2011 | Independent Director |
J. Kenneth Glass |
66 | 2004 | Independent Director |
Kenneth Robinson |
58 | 2008 | Independent Director |
Biographies
| Name | Description |
|---|---|
Joseph Hyde |
Mr. Joseph R. Hyde, III., is Independent Chairman of the Board of GTx Inc. Since 1989, Mr. Hyde has been the sole stockholder and President of Pittco Holdings, Inc., a private institutional investment company. Since 1996, when Mr. Hyde made a substantial contribution to support Dr. Steiner’s research, Mr. Hyde has been instrumental in forming and financing GTx and is stockholder. Mr. Hyde was the Chairman of the Board of Directors of AutoZone, Inc. (NYSE: AZO) from 1986 to 1997 and the Chief Executive Officer of AutoZone from 1986 to 1996. From March 2005 to June 2007, Mr. Hyde served as the non-executive chairman of the Board of Directors of AutoZone, Inc., and continues to serve as a member of the Board. He was also Chairman and Chief Executive Officer of Malone & Hyde, Inc., AutoZone’s former parent company, from 1972 until 1988. Mr. Hyde also served as a director of FedEx Corporation (NYSE: FDX) from 1977 to 2011. As stockholder and with a long history of serving as both Chairman and Chief Executive Officer of a publicly-traded company and a member of the board of directors of other public companies, Mr. Hyde has continued to serve as a principal architect of public company governance structure, and is the primary advisor to senior management on all matters of strategic importance. |
Marc Hanover |
Mr. Marc S. Hanover is President, Chief Operating Officer of GTx Inc . Mr. Hanover also served as a member of Board of Directors until August 2011. Prior to joining GTx, Mr. Hanover was a founder of Equity Partners International, Inc., a private equity firm in Memphis, Tennessee, and participated as a founder and investor in three healthcare companies. From 1985 to 1997, Mr. Hanover was a Senior Vice President and a member of the Executive Management Committee of National Bank of Commerce in Memphis, Tennessee. Mr. Hanover holds a B.S. in Biology from the University of Memphis and a MBA in Finance from the University of Memphis. |
Mitchell Steiner |
Dr. Mitchell S. Steiner, M.D., F.A.C.S., is Chief Executive Officer, Vice Chairman of the Board of GTx Inc . He is a co-founder of GTx. From 1995 to 2003, Dr. Steiner held numerous academic appointments, including Chairman and Professor of Urology, Director of Urologic Oncology and Research and the Chair of Excellence in Urologic Oncology at the University of Tennessee. Since 2003, Dr. Steiner has continued to serve on the faculty at the University of Tennessee. Dr. Steiner holds a B.A. in Molecular Biology from Vanderbilt University and an M.D. from the University of Tennessee, and performed his surgery and urologic training at The Johns Hopkins Hospital. Dr. Steiner serves as Chief Executive Officer to GTx, and is responsible for formulating the overall product development and commercial strategies for GTx. |
Mark Mosteller |
Mr. Mark E. Mosteller, CPA, is Chief Financial Officer, Vice President of GTx Inc . He has served as Chief Financial Officer since August 2001 and was appointed Vice President on January 20, 2005. From April 1997 to August 2001, Mr. Mosteller was an Executive Vice President of Union Planters Bank National Association, a subsidiary of Union Planters Corporation and Chief Operating Officer of Union Planters Mortgage. From 1994 to 1997, Mr. Mosteller was the Chief Financial Officer of Boatmen’s National Mortgage, Inc., the mortgage subsidiary of Boatmen’s Bancshares, Inc. From 1984 to 1994, Mr. Mosteller served as a Senior Manager in Audit Services at Ernst & Young LLP. Mr. Mosteller is a Certified Public Accountant and holds a B.S. in Accounting from the University of Tennessee. |
James Dalton |
Dr. James T. Dalton, Ph.D., is Vice President, Chief Scientific Officer of GTx Inc . Prior to that he served as Vice President, Preclinical Research and Development since January 2005. Dr. Dalton served as a scientific consultant to GTx from 1999 to 2005. Prior to joining GTx, Dr. Dalton held several academic appointments including Assistant and Associate Professor of Pharmaceutical Sciences in the College of Pharmacy at the University of Tennessee, Memphis (1992-2000) and Professor in the Division of Pharmaceutics, College of Pharmacy at The Ohio State University (2000-2007). SARMs were first discovered in Dr. Dalton’s research laboratories, and he is co-inventor on all SARM patents. Dr. Dalton holds a B.S. in Pharmacy from the University of Cincinnati and a Ph.D. in Pharmaceutics and Pharmaceutical Chemistry from The Ohio State University. |
Henry Doggrell |
Mr. Henry P. Doggrell is Vice President, Chief Legal Officer, Secretary of GTx Inc . He has served as General Counsel and Secretary since October 2001 and was appointed Vice President on January 20, 2005. From April 1998 to August 2001, Mr. Doggrell was Senior Vice President, Corporate Affairs at Buckeye Technologies, Inc., a specialty cellulose company, where he was responsible for matters including corporate finance, investor relations, mergers and acquisitions, intellectual property and licensing and strategic development. From 1996 to 1998, Mr. Doggrell served as General Counsel and Secretary of Buckeye Technologies. Prior to joining Buckeye Technologies, Mr. Doggrell was a partner of the Baker, Donelson, Bearman, Caldwell and Berkowitz law firm from 1988 to 1996, where he served as a member of the law firm management committee and Chair of the firm’s Corporate Securities department. Mr. Doggrell holds a B.S. in Commerce from the University of Virginia and a JD from Vanderbilt University. |
Michael Carter |
Dr. Michael G. Carter, M.D., Ch.B., F.R.C.P., is the Independent Director of GTx Inc. Dr. Carter has been a non-executive director of Micromet, Inc. (NASDAQ: MITI) and Santarus, Inc. (NASDAQ: SNTS) since 2004, and a non-executive director of Fulcrum Pharma, PLC (AIM: FUL) from 2005 to 2010. Dr. Carter was a member of the Advisory Board of Paul Capital Royalty Fund from 2005 to 2008, and has been a venture partner with SV Life Sciences Advisers, LLP since 1998 and a member of the strategic advisory board of Cowen Healthcare Royalty Partners since September 2009. Dr. Carter was the non-executive chairman of Metris Therapeutics, Ltd., a biotechnology firm specializing in women’s healthcare from 1999 to 2008. Dr. Carter served on the Pharmaceutical Board of Zeneca Pharmaceuticals, a predecessor company of AstraZeneca, and held various positions with Zeneca from 1984 to 1998, including International Medical Director and International Marketing Director. From 1985 to 1995, Dr. Carter served as a member of the U.K. Government’s Medicines Commission. Dr. Carter is an Elected Fellow of the Royal Pharmaceutical Society, Faculty of Pharmaceutical Medicine, and of the Royal College of Physicians of Edinburgh. Dr. Carter holds a bachelor’s degree in pharmacy from London University (U.K.) and a medical degree from Sheffield University Medical School (U.K.). |
Barrington Furr |
Prof. Dr. Barrington J.A. Furr, Ph.D., is Independent Director of GTx, Inc. Dr. Furr holds a Ph.D. in Reproductive Endocrinology from the University of Reading (United Kingdom). From 1972 to 2005, he worked for AstraZeneca and its predecessor companies. Following the 1999 merger of Zeneca with Astra, Dr. Furr was appointed Chief Scientist and Head of Project Evaluation at AstraZeneca. Dr. Furr serves as a non-executive director of the Medicines and Healthcare products Regulatory Agency (MHRA) of the Department of Health of the United Kingdom. He also serves as a non-executive director of the international animal genetics company, Genus plc (LSE:GNS), and he was recently appointed as the non-executive chairman of Llangarth Limited, a drug consultancy company. Dr. Furr has been recognized for his work on Zoladex®, the LHRH agonist for the first line treatment of advanced prostate cancer, and Casodex®, the selling anti-androgen in the United States, Europe and Japan. He was awarded the Society for Drug Research Drug Discovery Award and the Jubilee Medal of the Society of Endocrinology. For his services to cancer drug discovery, he was made an Officer of the Order of the British Empire in January 2000. |
J. Kenneth Glass |
Mr. J. Kenneth Glass is Independent Director of GTx Inc. Mr. Glass retired as Chairman of the Board, President and Chief Executive Officer of First Horizon National Corporation (NYSE: FHN), or First Horizon, as of January 29, 2007. Mr. Glass was named President and Chief Executive Officer of First Horizon in July 2002, and he also became First Horizon’s Chairman of the Board in January 2004. From 2003 through 2007, Mr. Glass served as a director of FedEx Corporation (NYSE: FDX). From July 2001 through July 2002, Mr. Glass was President and Chief Operating Officer of First Horizon. From 1993 to 2001, Mr. Glass was Business Unit President of First Tennessee Bank. Mr. Glass received his B.A. in Accounting from Harding University and graduated from Harvard Business School’s Advanced Management Program. As Chairman and Chief Executive Officer of one of the banks in Tennessee, Mr. Glass was recruited to the GTx Board to provide financial and business leadership experience to the Board. |
Kenneth Robinson |
Dr. Kenneth S. Robinson, M.D.,M.Div., is Independent Director of GTx,Inc. From 2003 through 2007, Dr. Robinson served in the cabinet of Tennessee Governor Phil Bredesen as Commissioner of Health, and in April 2009, Dr. Robinson accepted an appointment to provide executive-level public health leadership and consultation as the Health Officer of Shelby County, Tennessee, the county in which GTx is located. In February 2011, Dr. Robinson was appointed as Public Health Policy Advisor for Shelby County, Tennessee. From 1982 through 1991, Dr. Robinson taught and practiced internal medicine at Vanderbilt University School of Medicine, and from 1991 through 2003, he was an Assistant Dean at the University of Tennessee College of Medicine. Since 1991, he has served as Pastor and Chief Executive of St. Andrew AME Church. Dr. Robinson holds a B.A., cum laude, from Harvard University, a M.D. from Harvard Medical School, and a Master of Divinity from Vanderbilt Divinity School. As a Harvard trained physician who has experience in overseeing the complexities of federal and state agencies’ provision of healthcare to elderly and indigent patients, Dr. Robinson brings to the GTx Board experience in governmental reimbursement related issues and the role of government in the development and delivery of healthcare services. |
Basic Compensation
| Name | Fiscal Year Total |
|---|---|
Joseph Hyde |
-- |
Marc Hanover |
796,284 |
Mitchell Steiner |
990,040 |
Mark Mosteller |
452,806 |
James Dalton |
581,185 |
Henry Doggrell |
506,932 |
Michael Carter |
-- |
Barrington Furr |
-- |
J. Kenneth Glass |
-- |
Kenneth Robinson |
-- |
As Of 30 Dec 2012
Options Compensation
| Name | Options | Value |
|---|---|---|
Joseph Hyde |
0 | 0 |
Marc Hanover |
0 | 0 |
Mitchell Steiner |
0 | 0 |
Mark Mosteller |
97,500 | 643,675 |
James Dalton |
75,000 | 0 |
Henry Doggrell |
185,250 | 196,180 |
Michael Carter |
0 | 0 |
Barrington Furr |
0 | 0 |
J. Kenneth Glass |
0 | 0 |
Kenneth Robinson |
0 | 0 |
| Name | Shares Traded | Price |
|---|---|---|
HYDE JOSEPH REEVES III |
3,373 | $4.04 |
ROBINSON KENNETH S |
2,754 | $4.04 |
FURR BARRINGTON J A |
1,779 | $4.04 |
DALTON JAMES T |
20,000 | $5.20 |
DALTON JAMES T |
20,000 | $2.65 |
SEAR TIMOTHY R G |
2,946 | $4.20 |
FURR BARRINGTON J A |
1,592 | $4.20 |
HYDE JOSEPH REEVES III |
3,899 | $4.20 |
CARTER MICHAEL GREENWOOD |
655 | $4.20 |
ROBINSON KENNETH S |
3,125 | $4.20 |
SEAR TIMOTHY R G |
1,801 | $4.58 |
ROBINSON KENNETH S |
1,801 | $4.58 |
HYDE JOSEPH REEVES III |
1,801 | $4.58 |
FURR BARRINGTON J A |
1,174 | $4.58 |
CARTER MICHAEL GREENWOOD |
2,211 | $4.58 |
GLASS J KENNETH |
10,000 | $3.76 |
STEINER MITCHELL SHUSTER |
25,035 | $3.67 |
STEINER MITCHELL SHUSTER |
61,437 | $3.76 |
STEINER MITCHELL SHUSTER |
38,563 | $3.70 |
FURR BARRINGTON J A |
2,000 | $3.52 |
CARTER MICHAEL GREENWOOD |
3,587 | $3.52 |
ROBINSON KENNETH S |
2,557 | $3.52 |
SEAR TIMOTHY R G |
2,557 | $3.52 |
HYDE JOSEPH REEVES III |
2,344 | $3.52 |
STEINER MITCHELL SHUSTER |
1,137 | $3.50 |
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
